|
시장보고서
상품코드
2016153
피임약 시장 보고서 : 제품별, 연령층별, 유통 채널별, 지역별(2026-2034년)Contraceptive Drugs Market Report by Product, Age Group, Distribution Channel, and Region 2026-2034 |
||||||
세계의 피임약 시장 규모는 2025년에 174억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 260억 달러에 달하며, 2026-2034년에 CAGR 4.46%로 성장할 것으로 예측하고 있습니다.
피임약은 임신을 예방하고 출산율을 억제하기 위해 사용되는 약물을 말합니다. 이들은 배란을 억제하는 두 가지 여성 호르몬, 즉 에스트로겐과 프로게스틴을 이용해 합성됩니다. 이 호르몬은 자궁경부 점액을 두껍게 하거나 자궁내막의 상태를 변화시켜 수정과 착상을 위해 정자가 자궁경부로 들어가는 것을 막습니다. 피임약은 여드름, 골다공증, 난소암, 난관 및 자궁 감염, 월경전증후군(PMS)의 위험 감소에 도움이 됩니다. 그 결과, 가임기 여성의 원치 않는 임신을 예방하기 위해 의료진에 의해 처방되고 있습니다. 현재 주로 경구제, 주사제, 외용제 형태로 제공되고 있습니다.
피임약 시장 동향:
세계 피임약 시장을 촉진하는 주요 요인 중 하나는 가족계획에 대한 소비자의 인식 증가, 인구 증가, 의도하지 않은 임신의 증가입니다. 이와 함께 최적의 안전성과 더 나은 임상 결과 등 여러 가지 장점으로 인해 의료진들이 전통적 피임법에서 현대적 피임법으로 눈을 돌리고 있는 것도 또 다른 성장 요인으로 작용하고 있습니다. 또한 미국 식품의약국(FDA)을 비롯한 여러 규제 당국의 잦은 신약 승인도 시장 성장을 지원하고 있습니다. 또한 질내 pH 수준을 유지해 정자가 생존하기 어려운 환경을 조성하는 젤라틴 캡슐과 비호르몬성 질 젤의 등장도 시장 성장에 힘을 보태고 있습니다. 이와 더불어, 지속적인 연구개발(R&D) 활동과 비정부기구(NGO) 및 보건기관의 피임법, 여성 건강 및성 건강에 대한 소비자 인식 개선 노력은 시장 성장을 확실히 촉진하고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 피임약 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 연령층별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSAThe global contraceptive drugs market size reached USD 17.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 26.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.46% during 2026-2034.
Contraceptive drugs refer to birth control medications that are used to prevent pregnancy and control the birth rate. They are synthetically formulated using two female hormones, namely estrogen and progestin, which prevent ovulation. These hormones also thicken cervical mucus or alter the womb lining to prohibit the entrance of sperm into the cervix for fertilization and implantation. Contraceptive drugs assist in lowering the risks of acne, bone thinning, ovarian cancer, infections in the fallopian tubes and uterus, and premenstrual syndrome (PMS). As a result, they are administered by healthcare practitioners to inhibit unwanted pregnancy amongst women of childbearing age. At present, they are mainly available in oral, injectable, and topical formulations.
CONTRACEPTIVE DRUGS MARKET TRENDS:
One of the key factors driving the global contraceptive drugs market is the rising consumer consciousness regarding family planning, the increasing population, and the rising instances of unintended pregnancies. In line with this, the shifting inclination of healthcare practitioners toward modern contraceptive methods over conventional procedures, owing to their multiple benefits, including optimal safety, and better clinical outcomes, are acting as another growth-inducing factor. Additionally, the frequent approvals of novel medications by several regulatory bodies, such as the food and drug administration (FDA), are supporting the market growth. Moreover, the advent of gelatin capsules and non-hormonal vaginal gels that create an inhospitable environment for sperm to sustain by maintaining vagina pH levels is impelling the market growth. Apart from this, continuous research and development (R&D) activities and the favorable initiatives undertaken by non-governmental organizations (NGOs) and health agencies to sensitize consumers about contraception techniques, women's health, and sexual wellness are positively augmenting the market growth.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Oral Contraceptive Pills
- Injectable Contraceptives
- Topical Contraceptives
Breakup by Age Group:
- 15-24 years
- 25-34 years
- 35-44 years
- Above 44 years
Breakup by Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- Clinics
- Online Channel
- Public Channel and NGOs
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report provides a comprehensive analysis of the competitive landscape in the global contraceptive drugs market with detailed profiles of all major companies, including:
- Abbvie, Inc.
- Afaxys, Inc.
- Agile Therapeutics, Inc.
- Bayer AG
- HLL Lifecare Limited
- Organon group of companies
- Perrigo Company plc
- Pfizer Inc.
- Piramal Pharma Ltd.
- Teva Pharmaceuticals USA, Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global contraceptive drugs market in 2025?
2. What is the expected growth rate of the global contraceptive drugs market during 2026-2034?
3. What are the key factors driving the global contraceptive drugs market?
4. What has been the impact of COVID-19 on the global contraceptive drugs market?
5. What is the breakup of the global contraceptive drugs market based on the product?
6. What is the breakup of the global contraceptive drugs market based on the age group?
7. What is the breakup of the global contraceptive drugs market based on the distribution channel?
8. What are the key regions in the global contraceptive drugs market?
9. Who are the key players/companies in the global contraceptive drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Contraceptive Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Oral Contraceptive Pills
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Injectable Contraceptives
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Topical Contraceptives
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Age Group
- 7.1 15-24 years
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 25-34 years
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 35-44 years
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Above 44 years
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Retail Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Hospital Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Clinics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Online Channel
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Public Channel and NGOs
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbvie, Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Afaxys, Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Agile Therapeutics, Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.4 Bayer AG
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 HLL Lifecare Limited
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Organon group of companies
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Perrigo Company plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Piramal Pharma Ltd.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Teva Pharmaceuticals USA, Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.1 Abbvie, Inc.
